Dynavax Technologies Corporation
(Public, NASDAQ:DVAX) Watch this stockFind more results for
DVAX
Advertisement
Events
Nov 10, 2009
Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
Nov 3, 2009
Oppenheimer & Co. Healthcare Conference
Oct 22, 2009
Q3 2009 Earnings Conference Call
Oct 22, 2009
Q3 2009 Earnings Release
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | -369.05% | -71.54% |
| Operating margin | -369.22% | -51.54% |
| EBITD margin | - | -43.78% |
| Return on average assets | -65.66% | -25.14% |
| Return on average equity | -181.36% | -94.01% |
| Employees | 155 | - |
Address
2929 Seventh Street Suite 100
Berkeley, CA 94710
United States - Map
+1-510-8485100 (Phone)
+1-510-8485694 (Fax)
Berkeley, CA 94710
United States - Map
+1-510-8485100 (Phone)
+1-510-8485694 (Fax)
Website links
Company website:
http://www.dynavax.com/
http://www.dynavax.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
Dynavax Technologies Corporation discussed on blogs
Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
Pharma Pipeline News: Dynavax Completes Enrollment of First Cohort ...
- Pharma Service Provider
- Pharma Pipeline News
- Nov 19, 2009
Dynavax Technologies Corporation discussions
View all discussions »Description
Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline.
Officers and directors
| Arnold L. Oronsky Ph.D. | Chairman of the Board | |
| Dino Dina M.D. | President, Chief Executive Officer, Director | |
| Zbigniew Janowicz Ph.D | Chief Executive Officer, Managing Director of Rhein Biotech GmbH (Dynavax Europe) | |
| Jennifer Lew CPA | Vice President - Finance, Principal Accounting Officer | |
| Michael S. Ostrach | Vice President, Chief Business Officer, General Counsel | |
| Robert L. Coffman Ph.D. | Vice President, Chief Scientific Officer | |
| Dennis A. Carson M.D. | Director | |
| Denise M. Gilbert Ph.D. | Director | |
| Stanley A. Plotkin M.D. | Director | |
| Nancy L. Buc Esq. | Director |